RAJENDER APARASU to Young Adult
This is a "connection" page, showing publications RAJENDER APARASU has written about Young Adult.
Connection Strength
0.943
-
Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis. Mult Scler Relat Disord. 2025 Dec; 104:106750.
Score: 0.087
-
Factors associated with initial medication adherence with first-line therapy for depression. J Affect Disord. 2025 Dec 15; 391:120004.
Score: 0.086
-
Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
Score: 0.082
-
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
Score: 0.082
-
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
Score: 0.082
-
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
Score: 0.081
-
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
Score: 0.078
-
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
Score: 0.060
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.060
-
Quality of life of patients with Parkinson's disease and neurodegenerative dementia: A nationally representative study. Res Social Adm Pharm. 2016 Jul-Aug; 12(4):604-13.
Score: 0.043
-
Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012 Apr; 22(2):139-48.
Score: 0.034
-
The definition and prevalence of pediatric psychotropic polypharmacy. Psychiatr Serv. 2011 Dec; 62(12):1450-5.
Score: 0.033
-
Drug use trends for arthritis and other rheumatic conditions and effect of patient's age on treatment choice. N C Med J. 2011 Nov-Dec; 72(6):432-8.
Score: 0.033
-
Health care consequences of black-box warnings for antidepressants in the United States and Canada. Res Social Adm Pharm. 2010 Mar; 6(1):78-84.
Score: 0.028
-
Concomitant antipsychotic prescribing in US outpatient settings. Res Social Adm Pharm. 2009 Sep; 5(3):234-41.
Score: 0.027
-
Patients' willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States. J Am Pharm Assoc (2003). 2024 May-Jun; 64(3):102062.
Score: 0.019
-
Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
Score: 0.013
-
Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the medicaid program. J Affect Disord. 2018 08 01; 235:155-161.
Score: 0.013